InvestorsHub Logo
Followers 25
Posts 2345
Boards Moderated 0
Alias Born 06/20/2020

Re: moneycrew post# 154856

Thursday, 03/25/2021 7:34:32 PM

Thursday, March 25, 2021 7:34:32 PM

Post# of 233144

Lenz has zero eIND's or OLE's and is down 21 percent YTD

Leron has eIND andd OLE and is up 133 percent YTD.

Ok, lets compare-
Lenz will probably file a EUA by years end, Leron did already-

No brainer!!! Cytodyn's Leronlimab for the win


eINDs and OLE mean nothing. You don't get an EUA from anecdotal evidence. And CYDY's stock price opened the year at $5.69. But stock price doesn't matter. Data from double blind placebo controlled trials matter. See the pattern here? Trial data matters. Leronlimab has bad data. Lenzilumab will likely have spectacular data because it is anti-GM-CSF which has been proven to be the key to Covid.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News